Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy
Open Access
- 8 November 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (4) , 909-916
Abstract
The purpose of this study was to determine the functional proteomic characteristics of residual breast cancer and hormone receptor (HR)-positive breast cancer after neoadjuvant systemic chemotherapy, and their relationship with patient outcomes. Reverse phase protein arrays of 76 proteins were carried out. A boosting approach in conjunction with a Cox proportional hazard model defined relapse predictors. A risk score (RS) was calculated with the sum of the coefficients from the final model. Survival outcomes and associations of the RS with relapse were estimated. An independent test set was used to validate the results. Test (n = 99) and validation sets (n = 79) were comparable. CoxBoost revealed a three-biomarker (CHK1pS345, Caveolin1, and RAB25) and a two-biomarker (CD31 and Cyclin E1) model that correlated with recurrence-free survival (RFS) in all residual breast cancers and in HR-positive disease, respectively. Unsupervised clustering split patients into high- and low risk of relapse groups with different 3-year RFS (P ≤ 0.001 both). RS was a substantial predictor of RFS (P = 0.0008 and 0.0083) after adjustment for other substantial characteristics. Similar results were found in validation sets. We found models that independently predicted RFS in all residual breast cancer and in residual HR-positive disease that may represent potential targets of therapy in this resistant disease.Keywords
Funding Information
- Komen for the Cure Catalyst Award (1K23CA121994-01, KG090341)
- American Cancer Society Research Scholar (121329-RSG-11-187-01-TBG)
- National Cancer Institute through The University of Texas MD Anderson's Cancer Center (P30 CA016672)
This publication has 30 references indexed in Scilit:
- Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerClinical Proteomics, 2011
- A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersClinical Proteomics, 2010
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 2009
- The Emerging Role of the RAB25 Small GTPase in CancerTraffic, 2009
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresProceedings of the National Academy of Sciences, 2009
- Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast CancerClinical Cancer Research, 2009
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- Caveolin-1 Mutations in Human Breast CancerThe American Journal of Pathology, 2006
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006
- Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other FactorsJournal of Clinical Oncology, 2006